A Dose-ranging Clinical Trial to Study the Efficacy and Safety of DR-2031 for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients

Trial Information

A Dose-ranging Clinical Trial to Study the Efficacy and Safety of DR-2031 for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients

This is a study to compare the efficacy and safety of 3 doses of DR-2031 to placebo when
used as "add-on" therapy for prostate cancer in patients with mild to moderate vasomotor
symptoms (hot flashes) following surgical or medical castration. All prostate cancer
therapy must be stable for at least 45 days before entering the study and must remain stable
throughout this 12-week study. To be eligible for this study prostate cancer patients must
have undergone bilateral orchiectomy or medical castration utilizing LHRH analogues (LHRH
agonists or LHRH antagonists) with or without additional antiandrogen therapy. Patients must
have at least 21 moderate to severe hot flashes weekly.

Patients will maintain a daily paper diary to record the frequency and severity of hot
flashes during the treatment period. In addition, a brief physical evaluation will be done,
diaries will be reviewed and any adverse events will be recorded at each follow-up
evaluation.